Article
Storytelling, Awareness, and the Race Against Time in Duchenne Muscular Dystrophy
A conversation with advocate Thomas Bartlett on why storytelling and public awareness, as much as science, drive funding, policy, and access in Duchenne.
Duchenne Muscular Dystrophy
Understanding a disease where time matters.
DMD is a progressive genetic condition that slowly weakens muscles, affecting mobility, breathing, and the heart. This site is an independent, source-linked resource for families, clinicians, and the curious.
Informational content only. Always consult qualified healthcare professionals for clinical decisions.
- male births affected by DMD
- 1 in ~3,500
- when symptoms typically appear
- Ages 2–5
- when many lose ambulation
- Ages 10–13
- care: neuro, cardiac, respiratory
- Multi-system
Approximate figures drawn from public medical sources (MDA, NIH MedlinePlus, Duchenne UK). Outcomes vary widely between individuals.
What is DMD
A rare, progressive muscle disease
Duchenne Muscular Dystrophy (DMD) is a genetic disorder caused by mutations in the gene that encodes dystrophin, a protein muscles need to stay intact. Without functional dystrophin, muscle fibers gradually break down and are replaced by scar tissue.
Who it affects
DMD almost exclusively affects boys, because the dystrophin gene is on the X chromosome. It is estimated to occur in roughly 1 in every 3,500–5,000 male births.
What causes it
Mutations in the DMD gene, most often deletions, prevent the body from making functional dystrophin. Without it, repeated muscle contractions cause cumulative cellular damage.
How it progresses
Symptoms typically appear between ages 2–5. Mobility declines through childhood; respiratory and cardiac function become primary concerns in adolescence and adulthood.
Disease course
How DMD progresses over time
DMD follows a recognizable trajectory, though timing varies between individuals. Standards of care can affect outcomes meaningfully, which is why early diagnosis matters.
- Ages 2–5Early signsDelayed motor milestones, frequent falls, difficulty climbing stairs, calf enlargement, and a characteristic way of pushing on the thighs to stand (Gowers' sign).
- Ages 6–12Loss of ambulationWalking becomes progressively harder. Many children use a wheelchair full-time around ages 10–13, though corticosteroids and physiotherapy can delay this transition.
- Teen yearsUpper body and respiratory involvementUpper limb strength declines. Scoliosis may develop. Respiratory muscles weaken, often requiring non-invasive ventilation, especially overnight.
- AdulthoodCardiac and respiratory careCardiomyopathy and respiratory insufficiency become the leading clinical concerns. With modern multidisciplinary care, life expectancy has improved significantly in recent decades.
Symptoms & diagnosis
Recognizing DMD early
Earlier diagnosis allows earlier intervention. Newborn screening is not universal, so awareness among parents and pediatricians remains critical.
Early symptoms
- Delayed walking (typically beyond 18 months)
- Difficulty running, jumping, or climbing stairs
- Frequent falls
- Calf enlargement (pseudohypertrophy)
- Gowers' sign, where a child climbs up their own legs to stand
- Speech or learning delays in some cases
Confirming diagnosis
A markedly elevated serum creatine kinase (CK) level is an early clue. Diagnosis is then confirmed through genetic testing, which identifies the specific mutation in the DMD gene. Muscle biopsy is used less commonly today but can still be informative.
Current treatments
What is available today
There is no cure for DMD. Current treatments aim to slow progression, preserve function, and manage complications. New therapies continue to be studied, with varying eligibility, evidence, and access.
Corticosteroids
Prednisone and deflazacort remain a cornerstone of care, shown to prolong ambulation and preserve respiratory and cardiac function for many patients.
Physiotherapy & orthotics
Stretching, low-impact exercise, ankle-foot orthoses, and equipment to support posture and mobility throughout the disease course.
Cardiac & respiratory care
ACE inhibitors, beta blockers, and assisted ventilation (often non-invasive) help manage the cardiac and respiratory complications that dominate later stages.
Targeted & gene therapies
Exon-skipping medications and a gene therapy have received regulatory authorizations in some jurisdictions for specific patient subgroups. Eligibility, evidence, and access vary widely.
This summary is informational. Treatment decisions must be made by qualified clinicians familiar with the patient's full clinical picture.
Living with DMD
Care is multidisciplinary
Standards of care call for coordinated input from neurology, cardiology, pulmonology, orthopedics, physiotherapy, nutrition, psychology, and social work. Families are part of the care team.
Specialist clinics
Many countries have dedicated neuromuscular clinics that coordinate the multiple specialties involved in DMD care.
Mental health
DMD affects the whole family. Mental health support for patients, siblings, and caregivers is an explicit part of recommended care.
Education & inclusion
School accommodations, accessibility planning, and assistive technology help young people remain engaged in education and social life.
Research & hope
A field moving, unevenly
DMD is one of the most actively studied rare diseases. Several therapeutic strategies are being investigated, including exon skipping, gene therapy, gene editing, and anti-fibrotic and anti-inflammatory approaches. Progress is real, but access, cost, and evidence standards differ between regions.
The challenge facing modern healthcare systems is not only scientific. It is also about how new therapies are evaluated, priced, and made available to the patients who could benefit. Our articles explore these questions through reported stories and analysis, with sources linked.
Latest from us
Articles and posts
Articles
See all → Article
The Duchenne Lottery: Why Where a Child Lives May Now Matter More Than Ever
ELEVIDYS, the first Duchenne gene therapy, is approved in the US and Japan but rejected in Europe, leaving a child's access increasingly shaped by geography.
Article
The Same Disease, Different Countries: What Duchenne Parents in America and Georgia Reveal About Access, Hope, and Time
A reported comparison of how Duchenne families in the United States and Georgia experience access, advocacy, and the urgency of time.
From the blog
See all → Blog
Finding and Choosing a Duchenne Care Center
Expert, multidisciplinary care improves outcomes in Duchenne. How to find a specialist center, what good care looks like, and when to seek a second opinion.
Blog
Understanding Your Child's DMD Mutation and Treatment Eligibility
The exact DMD gene change matters. How deletions, duplications, and point mutations differ, and why the specific mutation shapes eligibility for some treatments.
Blog
Heart Medications in Duchenne: Protecting the Heart Before Symptoms
The heart needs protecting in Duchenne, often before symptoms. How medicines like ACE inhibitors and beta blockers help, when they start, and why early matters.